S
S. G. F. Wassilak
Researcher at National Institutes of Health
Publications - 4
Citations - 768
S. G. F. Wassilak is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Whooping cough & Vaccination. The author has an hindex of 3, co-authored 4 publications receiving 750 citations.
Papers
More filters
Journal ArticleDOI
A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis
Donato Greco,Stefania Salmaso,Paola Mastrantonio,Marina Giuliano,Alberto Eugenio Tozzi,A. Anemona,M L Ciofi Degli Atti,Anna Giammanco,Pietro Panei,William C. Blackwelder,D. L. Klein,S. G. F. Wassilak +11 more
TL;DR: The two acellular DTP vaccines studied were safe, immunogenic, and efficacious against pertussis, whereas the efficacy of the whole-cell DTP vaccine was unexpectedly low.
Journal ArticleDOI
Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines
Stefania Salmaso,Paola Mastrantonio,S. G. F. Wassilak,Marina Giuliano,A. Anemona,Anna Giammanco,Alberto Eugenio Tozzi,Ciofi degli Atti Ml,Donato Greco +8 more
TL;DR: A large, randomized, placebo-controlled clinical trial in Italy on two three-component pertussis vaccines, given as DTaP in infancy, found each vaccine to be 84% efficacious through the average age of 24 months.
Journal ArticleDOI
Incidence of invasive Haemophilus influenzae type b disease in Italian children
Alberto Eugenio Tozzi,Stefania Salmaso,M L Ciofi Degli Atti,Pietro Panei,A. Anemona,Gabriella Scuderi,S. G. F. Wassilak +6 more
TL;DR: The incidence and epidemiology of invasive Hib disease in Italy are comparable to those reported from other European countries, and cost-benefit analyses are needed for planning Italian vaccination policy.
Journal Article
Differences by antigen in seroconversion: sensitivity, specificity and bias in the serological confirmation of pertussis.
TL;DR: Vaccine efficacy of the most efficacious acellular pertussis vaccines in the three recent placebo-controlled clinical trials, when estimated using the primary clinical case criterion, does not change substantially with the inclusion of serological confirmation in addition to culture confirmation.